A Multicenter, Open-Label, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naive, KRAS-Mutant, Metastatic Colorectal Cancer (mCRC)

Trial Profile

A Multicenter, Open-Label, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naive, KRAS-Mutant, Metastatic Colorectal Cancer (mCRC)

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Etirinotecan pegol (Primary) ; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 09 Aug 2017 This trial has been discontinued in Belgium, as per European Clinical Trials Database record.
    • 24 Feb 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 05 Aug 2014 Planned primary completion date changed from 1 Jun 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top